Published in Mol Endocrinol on December 12, 2008
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J (2011) 2.55
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res (2009) 1.80
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol (2014) 1.21
Survival strategies of a sterol auxotroph. Development (2010) 1.16
SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest (2014) 1.10
Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PLoS One (2013) 1.09
INPP4B: the new kid on the PI3K block. Oncotarget (2011) 1.07
Transcriptional switches: chemical approaches to gene regulation. J Biol Chem (2010) 1.02
Isotretinoin and FoxO1: A scientific hypothesis. Dermatoendocrinol (2011) 1.02
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate (2012) 1.01
Aging and dry eye disease. Exp Gerontol (2012) 0.97
Unraveling the role of FoxOs in bone--insights from mouse models. Bone (2011) 0.96
Potential role of FoxO1 and mTORC1 in the pathogenesis of Western diet-induced acne. Exp Dermatol (2013) 0.95
Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci (2014) 0.95
FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. Prostate (2013) 0.94
Over-stimulation of insulin/IGF-1 signaling by western diet may promote diseases of civilization: lessons learnt from laron syndrome. Nutr Metab (Lond) (2011) 0.92
Dietary intervention in acne: Attenuation of increased mTORC1 signaling promoted by Western diet. Dermatoendocrinol (2012) 0.92
Structural features discriminate androgen receptor N/C terminal and coactivator interactions. Mol Cell Endocrinol (2011) 0.90
Glucocorticoid receptor cofactors as therapeutic targets. Curr Opin Pharmacol (2010) 0.89
Activation of FOXO1 is critical for the anticancer effect of methylseleninic acid in prostate cancer cells. Prostate (2010) 0.86
Targeting the Androgen Receptor by Taxol in Castration-Resistant Prostate Cancer. Mol Cell Pharmacol (2010) 0.84
The role of androgen and androgen receptor in skin-related disorders. Arch Dermatol Res (2012) 0.83
Analysis of interdomain interactions of the androgen receptor. Methods Mol Biol (2011) 0.82
Linking diet to acne metabolomics, inflammation, and comedogenesis: an update. Clin Cosmet Investig Dermatol (2015) 0.81
Enhanced hematopoietic stem cell function mediates immune regeneration following sex steroid blockade. Stem Cell Reports (2015) 0.80
Mechanism of androgen receptor corepression by CKβBP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer. Mol Cell Endocrinol (2013) 0.77
Combination effects of dietary soy and methylselenocysteine in a mouse model of prostate cancer. Prostate (2013) 0.76
Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention. Transl Med (Sunnyvale) (2012) 0.75
Milk disrupts p53 and DNMT1, the guardians of the genome: implications for acne vulgaris and prostate cancer. Nutr Metab (Lond) (2017) 0.75
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene (2005) 7.50
A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell (2006) 5.36
Genes that regulate both development and longevity in Caenorhabditis elegans. Genetics (1995) 5.09
Formation of the androgen receptor transcription complex. Mol Cell (2002) 4.93
Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science (2003) 4.32
Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1999) 4.19
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol (2007) 3.89
Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science (2008) 3.80
A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell (2002) 3.73
Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem (2004) 3.51
Cancer statistics, 1993. CA Cancer J Clin (1993) 3.43
Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst (1999) 3.41
The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol Cell (1998) 3.21
Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis (1997) 2.97
FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem (2002) 2.90
FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem (2000) 2.58
The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol (1999) 2.57
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res (2007) 2.04
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem (1995) 2.02
Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem (2002) 2.01
Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci U S A (2003) 1.99
Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci U S A (2006) 1.93
Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol (1999) 1.93
Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem (1997) 1.92
The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol (1999) 1.70
AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol (2003) 1.68
Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem (1995) 1.54
Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Mol Endocrinol (2003) 1.47
Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem (2007) 1.43
Recent advances in androgen receptor action. Cell Mol Life Sci (2003) 1.34
Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol (1999) 1.32
Androgen receptor (AR) NH2- and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth. Mol Endocrinol (2004) 1.23
Chromatin opening and stable perturbation of core histone:DNA contacts by FoxO1. J Biol Chem (2007) 1.14
Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem (2001) 1.13
Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene (1999) 1.07
The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol (2004) 1.06
The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol (2003) 1.06
Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol (2002) 1.02
Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Mol Endocrinol (2001) 1.00
The use of androgen receptor amino/carboxyl-terminal interaction assays to investigate androgen receptor gene mutations in subjects with varying degrees of androgen insensitivity. J Clin Endocrinol Metab (2003) 0.98
Selective activation of the probasin androgen-responsive region by steroid hormones. J Mol Endocrinol (1999) 0.90
GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. Biol Chem (2005) 0.90
An androgen-dependent upstream enhancer is essential for high levels of probasin gene expression. Endocrinology (2003) 0.83
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
Acetylation and deacetylation of non-histone proteins. Gene (2005) 6.87
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn (2012) 3.54
The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene (2005) 3.42
Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med (2002) 3.20
Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol (2012) 3.18
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A (2013) 2.99
Retracted Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem (2002) 2.97
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
Retracted Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem (2003) 2.89
TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res (2006) 2.83
Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol (2004) 2.75
SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol (2007) 2.47
Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res (2003) 2.43
SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell (2007) 2.42
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res (2010) 2.39
Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. Nat Cell Biol (2010) 2.37
Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science (2005) 2.31
Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J (2005) 2.30
Expression pattern shifts following duplication indicative of subfunctionalization and neofunctionalization in regulatory genes of Arabidopsis. Mol Biol Evol (2005) 2.18
Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest (2007) 2.17
Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem (2004) 2.11
Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. Genes Dev (2003) 2.08
Anni 2.0: a multipurpose text-mining tool for the life sciences. Genome Biol (2008) 2.04
Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci (2013) 2.04
Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol (2006) 2.01
Exosomes as biomarker treasure chests for prostate cancer. Eur Urol (2010) 1.94
Functional expression of the olfactory signaling system in the kidney. Proc Natl Acad Sci U S A (2009) 1.90
Gene expression profiling of the human prostate zones. BJU Int (2006) 1.86
Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res (2006) 1.83
High-throughput microarray detection of olfactory receptor gene expression in the mouse. Proc Natl Acad Sci U S A (2004) 1.82
Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology (2004) 1.76
AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci (2005) 1.72
CoPub Mapper: mining MEDLINE based on search term co-publication. BMC Bioinformatics (2005) 1.71
Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res (2008) 1.68
AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol (2003) 1.68
JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. EMBO J (2003) 1.67
Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol (2002) 1.67
Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer (2006) 1.64
MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem (2009) 1.63
Retracted Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem (2003) 1.63
Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res (2008) 1.62
Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol (2008) 1.58
Coactivators and corepressors of NF-kappaB in IkappaB alpha gene promoter. J Biol Chem (2005) 1.57
Genome-wide analysis of the cyclin family in Arabidopsis and comparative phylogenetic analysis of plant cyclin-like proteins. Plant Physiol (2004) 1.56
Floral gene resources from basal angiosperms for comparative genomics research. BMC Plant Biol (2005) 1.54
Large vessel involvement in ANCA-associated vasculitides: report of a case and review of the literature. Clin Rheumatol (2004) 1.50
Retracted AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem (2003) 1.49
Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun (2007) 1.45
Venn Mapping: clustering of heterologous microarray data based on the number of co-occurring differentially expressed genes. Bioinformatics (2003) 1.45
Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res (2007) 1.43
An efficient approach to finding Siraitia grosvenorii triterpene biosynthetic genes by RNA-seq and digital gene expression analysis. BMC Genomics (2011) 1.39
Text-derived concept profiles support assessment of DNA microarray data for acute myeloid leukemia and for androgen receptor stimulation. BMC Bioinformatics (2007) 1.37
Surface functionalization of gold nanoparticles using hetero-bifunctional poly(ethylene glycol) spacer for intracellular tracking and delivery. Int J Nanomedicine (2006) 1.35
SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem (2009) 1.33
Fgf9 from dermal γδ T cells induces hair follicle neogenesis after wounding. Nat Med (2013) 1.33
Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia. Clin Chem Lab Med (2009) 1.31
ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol (2011) 1.31
G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem (2003) 1.30
Androgen regulation of micro-RNAs in prostate cancer. Prostate (2010) 1.30
Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood (2005) 1.29
Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene (2004) 1.29
Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnol (2012) 1.28
Retracted Positive feedback regulation between Akt2 and MyoD during muscle differentiation. Cloning of Akt2 promoter. J Biol Chem (2002) 1.28
Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem (2004) 1.27
Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Mol Cell Proteomics (2009) 1.27
Structural basis of G protein-coupled receptor-G protein interactions. Nat Chem Biol (2010) 1.27
Negative modulation of androgen receptor transcriptional activity by Daxx. Mol Cell Biol (2004) 1.26
Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res (2009) 1.24
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther (2005) 1.24
Retracted MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem (2012) 1.22
Beyond microRNA--novel RNAs derived from small non-coding RNA and their implication in cancer. Cancer Lett (2013) 1.20
Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol (2009) 1.20
Focal adhesion kinase: exploring Fak structure to gain insight into function. Int Rev Cell Mol Biol (2011) 1.19
Repletion of atypical protein kinase C following RNA interference-mediated depletion restores insulin-stimulated glucose transport. J Biol Chem (2006) 1.17
Single-crystal nanoribbons, nanotubes, and nanowires from intramolecular charge-transfer organic molecules. J Am Chem Soc (2007) 1.17
Retracted Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway. J Biol Chem (2005) 1.17
Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int (2009) 1.16
VEGFR2 functions as an H2S-targeting receptor protein kinase with its novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch for hydrogen sulfide actions in vascular endothelial cells. Antioxid Redox Signal (2013) 1.16
Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res (2005) 1.16